openPR Logo
Press release

Orthomyxoviridae Infections Treatment Market to increase rapidly by 2020

10-06-2017 04:55 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research
Orthomyxoviridae Infections Treatment Market to increase

Orthomyxoviridae infections are caused by a large family of viruses spanning six genera. They are responsible for the occurrence of influenza amongst both humans and animals. Influenzavirus A, Influenzavirus B, Influenzavirus C, Isavirus, Thogotovirus and Quaranjavirus are the six different types of orthomyxoviridae. Each of these genera also include several serotypes or sub-types, Influenza A includes major sub-types such as H1N1, H1N2, H2N2, H3N1, H3N2, H3N8, H5N1, H5N2, H5N3, H5N8, H5N9, H7N1, H7N2, H7N3, H7N4, H7N7, H7N9, H9N2 and H10N7. Thogotovirus includes Batken, Dhori and Jos sub-types. Influenza B includes the Victoria and Yamagata sero-types. Orthomyxoviridae diseases are communicable and spread through infected food, feces and bird droppings, water and mucus in aerosol form. Influenza viruses are destroyed when exposed to bleach, 70% ethanol, aldehydes, oxidizing agents, and quaternary ammonium compounds. The viruses are also inactivated by raising temperatures above 56 °C for minimum of 60 minutes, and in acidic conditions. Avian flu has the highest risk and mortality with more than 800 cases per 100,000 across the world according to the Centers for Disease Control and Prevention.

Request Sample Copy of the Report@
 https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3496

The viruses replicate by beginning from endocytosis, where haemagglutinin protein fuses the viral envelope with the vacuole's membrane, releasing the viral RNA (vRNA) molecules, accessory proteins and RNA-dependent RNA polymerase into the cytoplasm. Due to the absence of RNA proofreading enzymes, the replication process makes a genetic error every 10,000 nucleotides thus mutating the virus on a very large scale. The genome of orthomyxovirus comprises six to eight segments of single stranded, linear and negative sense RNA. The complete genome is about 10,000 to 14,600 nucleotide long. Though the epidemic and mortality associated with orthomyxoviridae has been prevalent for almost 100 years yet the worst of them was 1918 pandemic which almost caused 20 million deaths across the globe of which 500,000 were in the United States. Sore throat, nonproductive cough and nasal discharge are some symptoms of the infection.  

Ease in transmission of virus through inhalation, coughing and living in close proximity of infected person is major divers for the growth of orthomyxoviridae Infections treatment market. Moreover, inclination of tier 1 pharmaceutical companies for developing novel therapeutics as a cure to the infection will further compliment for the growth of the market. Geographically market for Orthomyxoviridae infections treatment market is dominated by the developed economic countries owing to government funding, implementation of stringent regulations to develop cost effective drugs/vaccines and intense research activities by scholars at universities and private research centers. Market for orthomyxoviridae infections treatment in emerging economic countries is growing at a rapid pace pertaining to rise in incidences of influenza and H1N1 infections in past. Some of the prominent pipelined drugs in the market encompass Q-LAIV Flu Vac, FluBlok, Cholecalciferol, GSK2340272A, Resfenol, Relenza, Vaxigrip, Preflucel, Oseltamivir and others. Such a distinct pipeline profile clearly depicts the intense research activities conducted by the players operating the market. Living in close proximity with poultry and animal husbandry are another prominent factor for increasing orthomyxoviridae infection rate especially in underdeveloped and developing parts of Asia Pacific and Middle East countries. 

Some of the prominent companies operating and conducting research activities include Orthomyxoviridae Infections Therapeutics market include Baxter International Inc., AstraZeneca PLC, Vical Incorporated, Sanofi-Aventis, Generex Biotechnology Corporation, Novartis AG, AlphaVax, Inc., BioCryst Pharmaceuticals, Inc., CureVac GmbH, PepTcell Limited, Hawaii Biotech, Inc. and others. 

Request TOC of the Report@
 https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=3496

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
North America 
Asia Pacific 
Europe
Rest of the World  
This report provides comprehensive analysis of 
Market growth drivers 
Factors limiting market growth
Current market trends 
Market structure
Market projections for upcoming years 

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Orthomyxoviridae Infections Treatment Market to increase rapidly by 2020 here

News-ID: 760937 • Views:

More Releases from Transparency Market Research

Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights for the USD 15.9 Bn Market 2022-2031
Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights f …
The global handheld marijuana vaporizer market has witnessed remarkable growth in recent years, attributed to the increasing acceptance of medicinal marijuana and the demand for convenient and discreet consumption methods. Valued at US$ 5 billion in 2021, the market is projected to surge at a CAGR of 13.4% to reach US$ 15.9 billion by 2031. This article delves into the factors driving this growth, the evolving market landscape, and the
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And Competitors
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And …
The COVID-19 pandemic has precipitated a remarkable surge in the demand for disinfectant products, with a notable emphasis on disinfectant wipes as an essential tool in maintaining hygiene and preventing the spread of pathogens. This research report delves into the multifaceted landscape of the disinfectant wipes market, elucidating key trends, drivers, and innovations shaping the industry. 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=70359 Key Players and Market Developments Key players
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Study
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Stud …
The global 𝐭𝐢𝐬𝐬𝐮𝐞 𝐛𝐚𝐧𝐤𝐢𝐧𝐠 𝐦𝐚𝐫𝐤𝐞𝐭 reached a value of US$ 1,056.4 million in 2017 and is projected to nearly triple to US$ 2,903.3 million by 2026, with a robust Compound Annual Growth Rate (CAGR) of approximately 12.0% from 2018 to 2026. Factors such as increasing awareness about tissue donation, technological advancements, and a growing target patient population are anticipated to propel market growth during this period. Moreover, the market is expected
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
This report by Transparency Market Research, Inc. assesses the present state and future growth potential of the global 𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐜𝐥𝐨𝐬𝐮𝐫𝐞 𝐝𝐞𝐯𝐢𝐜𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭. It features a comprehensive executive summary, offering insights into various segments of the market. Additionally, the report provides detailed analysis and data on product, access type, application, end user, and regional segments within the global market. Vascular closure devices is estimated to reach a value of ~US$ 1 Bn

All 5 Releases


More Releases for Orthomyxoviridae

Equine Influenza Vaccine Market Comprehensive Insight by Growth Rate, Industry S …
The global equine influenza vaccine market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Equine influenza is a highly contagious respiratory disease. It occurs in horses and other Equidae that is caused by two subtypes of the influenza A virus of the Orthomyxoviridae family including H7N7 and H3N8. The major factor for the growth of the market is the rising initiatives and growing concern from
Influenza B Infection Market Notable Developments | AltraVax, Inc., Autoimmune T …
Global Influenza B Infection Market: Overview Influenza is commonly classified as type A, B, or C, depending on the protein composition of the virus. Influenza B infection is caused by influenzavirus B genera of the family Orthomyxoviridae and is found only in humans. Common symptoms of the infection include runny nose, chills, fever, muscle pain, sore throat, fatigue, coughing, and general weakness. Nausea and vomiting is also observed in some cases,
Influenza Diagnostics Market Size, Share | Industry Report 2026
The global Influenza Diagnostics Market was valued at $xx Billion in 2018 and is forecast to grow at a modest xx % CAGR between2018 and 2025, culminating in 2026 global sales of $xx Billion. Influenza Diagnostics is a test used to detect negative-sense standard RNA virus under the Orthomyxoviridae family known as “Flu”. It is a high spreadable viral disease of the respiratory passages of mammals and birds including us.
Influenza Vaccine Market - Global Industry Trends,Size,Status and Forecast 2018- …
Influenza is an infectious disease caused by the influenza virus. It is also known as flu. Influenza virus is a ribonucleic acid (RNA) virus that belongs to Orthomyxoviridae family. It is a helical shaped, single-stranded virus. Influenza A virus affects people of all age groups and causes moderate to severe illness, while the infection due to influenza B virus results in milder disease and affects pediatrics primarily. Human illness due
Global Orthomyxoviridae Infections Treatment Market Pegged for Robust Expansion …
Orthomyxoviridae infections are caused by a large family of viruses spanning six genera. They are responsible for the occurrence of influenza amongst both humans and animals. Influenzavirus A, Influenzavirus B, Influenzavirus C, Isavirus, Thogotovirus and Quaranjavirus are the six different types of orthomyxoviridae. Each of these genera also include several serotypes or sub-types, Influenza A includes major sub-types such as H1N1, H1N2, H2N2, H3N1, H3N2, H3N8, H5N1, H5N2, H5N3, H5N8,
Influenza B Infection Industry Perspective, Comprehensive Analysis and Forecast, …
Global Influenza B Infection Market: Overview Influenza is commonly classified as type A, B, or C, depending on the protein composition of the virus. Influenza B infection is caused by influenzavirus B genera of the family Orthomyxoviridae and is found only in humans. Common symptoms of the infection include runny nose, chills, fever, muscle pain, sore throat, fatigue, coughing, and general weakness. Nausea and vomiting is also observed in some cases,